These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 28651379)

  • 1. KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas.
    Tang H; Zhu H; Wang X; Hua L; Li J; Xie Q; Chen X; Zhang T; Gong Y
    J Mol Cell Biol; 2017 Aug; 9(4):315-324. PubMed ID: 28651379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
    Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
    Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
    Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
    J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KLF4
    von Spreckelsen N; Waldt N; Poetschke R; Kesseler C; Dohmen H; Jiao HK; Nemeth A; Schob S; Scherlach C; Sandalcioglu IE; Deckert M; Angenstein F; Krischek B; Stavrinou P; Timmer M; Remke M; Kirches E; Goldbrunner R; Chiocca EA; Huettelmaier S; Acker T; Mawrin C
    Acta Neuropathol Commun; 2020 Apr; 8(1):41. PubMed ID: 32245394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NANOG overexpression and its correlation with stem cell and differentiation markers in meningiomas of different WHO grades.
    Freitag D; McLean AL; Simon M; Koch A; Grube S; Walter J; Kalff R; Ewald C
    Mol Carcinog; 2017 Aug; 56(8):1953-1964. PubMed ID: 28345785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretory meningioma with KLF4 K409Q mutation in collision with glioma.
    Ruiz J; Capilla E; Díaz JF; Ruiz JA; Andrade J; Hernández T; Mollejo M; Meléndez B
    Clin Neuropathol; 2015; 34(6):322-9. PubMed ID: 26227255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase activity and expression of the telomerase catalytic subunit, hTERT, in meningioma progression.
    Simon M; Park TW; Leuenroth S; Hans VH; Löning T; Schramm J
    J Neurosurg; 2000 May; 92(5):832-40. PubMed ID: 10794298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of material from chromosome arm 1p during malignant progression of meningioma revealed by fluorescent in situ hybridization.
    Ishino S; Hashimoto N; Fushiki S; Date K; Mori T; Fujimoto M; Nakagawa Y; Ueda S; Abe T; Inazawa J
    Cancer; 1998 Jul; 83(2):360-6. PubMed ID: 9669820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of disabled-2 is common reduced in meningiomas.
    Zhang Z; Chen Y; Xie X; Tang J
    Neurol India; 2014; 62(1):57-61. PubMed ID: 24608456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.
    Reuss DE; Piro RM; Jones DT; Simon M; Ketter R; Kool M; Becker A; Sahm F; Pusch S; Meyer J; Hagenlocher C; Schweizer L; Capper D; Kickingereder P; Mucha J; Koelsche C; Jäger N; Santarius T; Tarpey PS; Stephens PJ; Andrew Futreal P; Wellenreuther R; Kraus J; Lenartz D; Herold-Mende C; Hartmann C; Mawrin C; Giese N; Eils R; Collins VP; König R; Wiestler OD; Pfister SM; von Deimling A
    Acta Neuropathol; 2013 Mar; 125(3):351-8. PubMed ID: 23404370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma.
    Lusis EA; Watson MA; Chicoine MR; Lyman M; Roerig P; Reifenberger G; Gutmann DH; Perry A
    Cancer Res; 2005 Aug; 65(16):7121-6. PubMed ID: 16103061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features.
    Yang SY; Park CK; Park SH; Kim DG; Chung YS; Jung HW
    J Neurol Neurosurg Psychiatry; 2008 May; 79(5):574-80. PubMed ID: 17766430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray Expression Data Identify DCC as a Candidate Gene for Early Meningioma Progression.
    Schulten HJ; Hussein D; Al-Adwani F; Karim S; Al-Maghrabi J; Al-Sharif M; Jamal A; Al-Ghamdi F; Baeesa SS; Bangash M; Chaudhary A; Al-Qahtani M
    PLoS One; 2016; 11(4):e0153681. PubMed ID: 27096627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Malignant progression to anaplastic meningioma: Neuropathology, molecular pathology, and experimental models.
    Cimino PJ
    Exp Mol Pathol; 2015 Oct; 99(2):354-9. PubMed ID: 26302177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Masked hypodiploidy in anaplastic meningiomas by duplication of the original clone found in atypical meningiomas: illustration of the evolution of genetic alterations.
    Ely EE; Guzman MA; Calvey LS; Batanian JR
    Neuropathology; 2014 Aug; 34(4):353-9. PubMed ID: 24612240
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intratumoral patterns of clonal evolution in meningiomas as defined by multicolor interphase fluorescence in situ hybridization (FISH): is there a relationship between histopathologically benign and atypical/anaplastic lesions?
    Sayagués JM; Tabernero MD; Maíllo A; Espinosa A; Rasillo A; Díaz P; Ciudad J; López A; Merino M; Gonçalves JM; Santos-Briz A; Morales F; Orfao A
    J Mol Diagn; 2004 Nov; 6(4):316-25. PubMed ID: 15507670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic landscape of meningioma.
    Yuzawa S; Nishihara H; Tanaka S
    Brain Tumor Pathol; 2016 Oct; 33(4):237-247. PubMed ID: 27624470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression.
    Wrobel G; Roerig P; Kokocinski F; Neben K; Hahn M; Reifenberger G; Lichter P
    Int J Cancer; 2005 Mar; 114(2):249-56. PubMed ID: 15540215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.